Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $145.00

Merck & Co., Inc. (NYSE:MRK) had its price target upped by Argus from $130.00 to $145.00 in a research note published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

MRK has been the subject of several other reports. BMO Capital Markets boosted their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Bank of America boosted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Barclays upped their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, Guggenheim lifted their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $135.50.

Merck & Co., Inc. Stock Up 2.0%

MRK stock opened at $135.57 on Tuesday. The stock has a 50-day simple moving average of $125.25 and a two-hundred day simple moving average of $119.83. The firm has a market capitalization of $334.49 billion, a PE ratio of 108.46, a PEG ratio of 5.73 and a beta of 0.19. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.68. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the prior year, the company posted $2.13 EPS. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares in the company, valued at $14,501,282.21. This trade represents a 9.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 over the last ninety days. Corporate insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of large investors have recently added to or reduced their stakes in MRK. Norges Bank bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $3,997,933,000. Wellington Management Group LLP boosted its stake in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after purchasing an additional 11,156,354 shares during the period. Cardano Risk Management B.V. bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $1,012,530,000. Jennison Associates LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $585,192,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Merck & Co., Inc. by 37.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock worth $1,973,983,000 after purchasing an additional 5,152,069 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
• Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
• Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
• Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
• Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
• Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.